Previous 10 | Next 10 |
Image source: The Motley Fool. ChemoCentryx Inc (NASDAQ: CCXI) Q3 2020 Earnings Call Nov 9, 2020 , 5:00 p.m. ET Operator Continue reading For further details see: ChemoCentryx Inc (CCXI) Q3 2020 Earnings Call Transcript
-- Study Showed T reatment with Avacopan A chieved Statistical Superiority in Sustaining Remission at 52 Weeks and G reater I mprovement in R enal F unction C ompared to the Prednisone Group -- MOUNTAIN VIEW, Ca...
ChemoCentryx (CCXI) announces that the European Medicines Agency ((EMA)) has accepted for review licensee Vifor Fresenius Medical Care Renal Pharma's marketing application seeking approval of avacopan for the treatment of a group of rare and severe autoimmune diseases called ANCA-associated v...
Companies have completed the EU regulatory application for marketing approval of avacopan Regulatory submission based on positive data from the pivotal P hase-III ADVOCATE trial of avacopan ST. GALLEN, Switzerland and MOUNT...
MOUNTAIN VIEW, Calif., Nov. 02, 2020 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the Company's third quarter 2020 financial results will be released after market close on Monday, November 9, 2020. ChemoCentryx executive management will host a conference call...
Humanigen starts dosing patients in Phase 3 COVID-19 vaccine trial. AbbVie reports positive topline data for AGN-190584 Phase 3 trial. ChemoCentryx reports Phase II AURORA data for Avacopan. For further details see: Humanigen Dosing Phase 3 Covid Patients, And Othe...
Gainers: [[UUU]] +57.2%. [[PINS]] +27.7%. [[CASH]] +12.9%. [[EGOV]] +9.2%. [[BXC]] +8.1%.Losers: [[BLKB]] -22.1%. [[CCXI]] -13.9%. [[INOV]] -10.1%. [[PI]] -8.4%. [[TDOC]] -4.4%. For further details see: UUU, PINS, CCXI and BLKB among after-hours movers
ChemoCentryx (CCXI) announces unsuccessful results from a Phase 2 clinical trial, AURORA, evaluating avacopan in patients with hidradenitis suppurativa ((HS)), a chronic skin condition characterized by the formation of painful lumps under the skin in areas such as the armpits, groin...
-- Avacopan demonstrates statistically significant dose-dependent improvement in HiSCR (Hidradenitis Suppurativa Clinical Response) vs. placebo in pre-specified Hurley Stage III (severe HS) patients at 12 weeks; numerical improvement observed with avacopan treatment in overall stu...
The following slide deck was published by ChemoCentryx, Inc. in conjunction with this event. For further details see: ChemoCentryx (CCXI) - Investor Presentation - Slideshow
News, Short Squeeze, Breakout and More Instantly...
AMGEN SUCCESSFULLY COMPLETES ACQUISITION OF CHEMOCENTRYX PR Newswire TAVNEOS ® (avacopan), a First-in-Class Medicine for Patients With Severe Active ANCA-Associated Vasculitis, Added to Inflammation Portfolio THOUSAND OAKS, Calif. , Oct. 20, ...
-- Planned posters and an oral presentation will highlight data from the trials that supported the approval of TAVNEOS ® (avacopan) for patients with ANCA-associated vasculitis; additional poster will cover expression of kidney C5aR -- SAN CARLOS, Calif., Oct. 17,...
-- Two poster presentations planned for CCX559, including results from ongoing Phase I clinical study in patients with advanced solid tumors, and preclinical evidence from murine model -- SAN CARLOS, Calif., Oct. 05, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), tod...